Mein Warenkorb

ActiveMax® Human DLL4 μBeads, premium grade (for cells)
DMF

User Reviews
Product Number/Spec
Price
Menge
MBS-C013-2.5mg
€1865.00
MBS-C013-10mg
€4565.00
ETA of in-stock products:3 business days
Gesamtanzahl Product Amount0

Product Details

  • Product
    Size
    Amount
    ActiveMax® Human DLL4 μBeads, premium grade (for cells)
    2.5 mg
    2.5×10⁷ beads
    ActiveMax® Human DLL4 μBeads, premium grade (for cells)
    10 mg
    1×10⁸ beads
  • Product Description

    ActiveMax® Human DLL4 μBeads, premium grade (for cells) are uniform, superparamagnetic beads of 5.5 µm in diameter immobilized with Human DLL4 Protein, expressed from human 293 cells (HEK293) and contains AA Ser 27 - Pro 524 (Accession # NP_061947.1 ).
    ActiveMax® Human DLL4 μBeads, premium grade (for cells) are produced under sterile manufacturing conditions (ISO 5) , and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.

  • Application

    ActiveMax® Human DLL4 μBeads, premium grade (for cells) can activate Notch signaling in hematopoietic stem/progenitor cells (HSPCs), mimicking DLL4+ epithelial cells in the thymus, and then drives T-lineage commitment and differentiation. It can be used for in vitro production of induced pluripotent stem cell derived T cells, such as inducing the differentiation from CD34+ cells to progenitor T cells to TCRαβ T cells in vitro, which provides a simple and robust tool to both study human T cell development and facilitate the development of engineered T cell therapies from renewable sources.

  • Reconstitution

    See Certificate of Analysis (CoA) for detailed instruction.

  • Storage

    This product is stable in storage under the following conditions: -20˚C for 12 months in lyophilized state. -70°C for 3 months under sterile conditions after reconstitution.

    Please avoid repeated freeze-thaw cycles after reconstitution. Immediate use after reconstitution is highly recommended.

  • Sterility

    Negative

  • Endotoxin

    Less than 0.002 EU per μg by the LAL method / rFC method.

  • Mycoplasma

    Negative

  • Important Note

    This product is for research use only and not intended for therapeutic or in vivo diagnostic use.

  • Formulation

    Please contact us for detailed information.

    Contact us for customized product form or formulation.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Kunden haben auch angesehen

Data Display

  • FACS Data

     DLL4 FACS

    Assay of human DLL4 protein on the μBeads surface by Flow cytometry.The human DLL4 conjugated on the μBeads (Cat. No. MBS-C013) surface were fluorescently stained using Human Anti-DLL4 Antibody, Mouse IgG1 and PE labeled anti-Mouse IgG1 Antibody, analyzed by flow cytometry (QC tested).

    Protocol
  • Application Data

     DLL4 APPLICATION DATA

    ActiveMax® Human DLL4 μBeads, premium grade (for cells) (Cat. No. MBS-C013) could efficiently induce hematopoietic stem cell differentiation into CD56+ NK cells after 25 days of culture, with high expression of CD56, NKp46, NKp30, and NKp44.

  •  DLL4 APPLICATION DATA

    The Cell Number of hcCD34P cells-derived CD7+ and CD5+ T-lymphoid progenitors After 21 Days of Culture. Combinations of ActiveMax® Human DLL4 μBeads, premium grade(for cells)(Cat.No.MBS-C013) and Cytokine could efficiently induce hcCD34P cells differentiation into CD7+ and CD5+ T-lymphoid progenitors after 21 days of culture.

  •  DLL4 APPLICATION DATA

    CD34+ CD45+ hematopoietic cells were co-cultured with Human DLL4 μBeads (Cat. No. MBS-C013) and differentiated over a 14-day period. Subsequent flow cytometric analysis was performed to evaluate the expression of T-cell progenitor markers CD5 and CD7. The results indicated that Human DLL4 μBeads (Cat. No. MBS-C013), in combination with supplementary growth factors, effectively promoted the differentiation of CD7+ cells as well as CD5+CD7+ double-positive T-cell progenitors. The induction efficiency was enhanced as the cell-to-bead ratio increased from 1:3 to 1:40. Based on both induction performance and cost-effectiveness, a cell-to-bead ratio of approximately 1:20 is recommended.

User Reviews
Publish Comment

Frontier Progress

 
Drug Development Progress
  • English Name:

    Delta-like protein 4

  • Category:

  • Listed Drugs Count:

    0 Details

  • Clinical Drugs Count:

    3 Details

  • Highest R&D Stage:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Kunden haben auch angesehen
  • Data Display
  • User Reviews
Kontaktieren Sie uns